Ironwood Capital Connecticut, a unit of Ironwood Capital, announced an investment in IsoPlexis, a venture-capital funded life sciences company developing a diagnostic platform to measure cellular immune response in patients. 
 
"IsoPlexis has developed a broad platform with enormous potential to advance personalized medicine and has demonstrated value to researchers focused on immuno-oncology, autoimmune and infectious diseases," stated John Strahley, Ironwood Capital managing director.

"Led by CEO Sean Mackay, the management team has done a great job to advance the science and address market needs.  We're excited to partner with IsoPlexis, its outstanding management team, investors and scientific advisors," stated Victor Budnick, Ironwood Capital senior managing director.
 
IsoPlexis develops cutting-edge tools to help researchers and clinicians find the immune cell subsets driving patient immune response.  The IsoPlexis platform provides intuitive analytics to visualize large amounts of cellular data, translating it into actionable patient information.  This functional data provides a more complete and accurate understanding of efficacy and safety, which ultimately improves patient outcomes.
 
"We welcome Ironwood Capital, our new local partner during this critical growth stage for IsoPlexis," commented Sean Mackay, co-founder and CEO of IsoPlexis.  "We believe that future advances in immunology will depend upon finding deeper information at the cellular level.  Ironwood's investment in the company will help us build out technologies to do just that."

Ironwood Capital is a Connecticut-based private equity firm that provides non-control growth capital to middle-market companies.  Ironwood Capital has invested, through its various partnerships, more than $600 million in over 100 companies across the United States, including $143.5 million in 44 Connecticut-based companies.  Ironwood Capital Connecticut works exclusively with Connecticut-based companies seeking capital across the entire financing spectrum from equity through senior debt.  Likewise, it seeks companies at every lifecycle stage from start-ups to mature companies.

IsoPlexis is a life sciences company developing a diagnostic platform that identifies a wide range of patient immune responses at the cellular level.  Its platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and informing physician decisions.  IsoPlexis is headquartered in Branford, Connecticut.